Physician profile
Joginder Singh
NPI 1538113907
$1,512.57
in general payments reported to CMS, 2019-2025
23 companies · $43.25 in 2025
The $43.25 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $413 · 2021: $283 · 2022: $17.77 · 2023: $240 · 2025: $43.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $240 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $239.59 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $353.86 | 2019-2020 | |
| Astellas Pharma US INC | $238.84 | 2019-2020 | |
| Exelixis INC. | $153.65 | 2019-2023 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $128.90 | 2020-2025 | Enhertu |
| Beigene USA, INC. | $125.00 | 2023 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $99.74 | 2019-2021 | |
| Abbvie INC. | $59.26 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.97 | 2020 | |
| Janssen Biotech, INC. | $49.65 | 2019 | |
| Merck Sharp & Dohme LLC | $37.21 | 2021-2022 | |
| Lilly USA, LLC | $28.75 | 2021 | |
| Amgen INC. | $23.36 | 2019 | |
| Morphosys, US INC. | $21.06 | 2021 | |
| Genzyme Corporation | $18.38 | 2021 | |
| Taiho Oncology, INC. | $15.60 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $15.00 | 2021 | |
| Pfizer INC. | $14.93 | 2021 | |
| Foundation Medicine, INC. | $14.45 | 2021 | |
| Eisai INC. | $14.28 | 2021 | |
| Daiichi Sankyo INC. | $13.54 | 2021 | |
| Glaxosmithkline, LLC. | $12.95 | 2021 | |
| Incyte Corporation | $12.69 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joginder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.